Serum S100A12 (EN-RAGE) levels in patients with decreased renal function and subclinical chronic inflammatory disease

Kidney and Blood Pressure Research

Volumn 34, Issue 6, 2011, Pages 457-464

  Zakiyanov, Oskar ^a   Kalousová, Marta ^a   Kříha, Vítězslav ^b   Zima, Tomáš ^a   Tesař, Vladimír ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CZECH TECHNICAL UNIVERSITY IN PRAGUE   (Czech Republic)

Author keywords

Calcium binding protein; Chronic kidney disease; EN RAGE; Hemodialysis; Inflammation; Protein; S100A12; sRAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALPHA 2 MACROGLOBULIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCIUM BINDING PROTEIN; FIBRINOGEN; OROSOMUCOID; PROTEIN S100A12; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; CHRONIC INFLAMMATION; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FUNCTION; LEUKOCYTE COUNT; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; AGED; BIOLOGICAL MARKERS; FEMALE; HUMANS; INFLAMMATION MEDIATORS; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; S100 PROTEINS;

EID: 79961113023     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000329291     Document Type: Article

References (44)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
2. Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N, European Uremic Toxin Work Group: Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005; 20: 1048-1056.
3. Ritz E, McClellan WM: Overview: Increased cardiovascular risk in patients with minor renal dysfunction: An emerging issue with far-reaching consequences. J Am Soc Nephrol 2004; 15: 513-516.
4. Knight EL, Rimm EB, Pai JK, Rexrode KM, Cannuscio CC, Manson JE, Stampfer MJ, Curhan GC: Kidney dysfunction, inflammation, and coronary events: A prospective study. J Am Soc Nephrol 2004; 15: 1897-1903.
5. Tripepi G, Mallamaci F, Zoccali C: Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: Searching for the best risk marker by multivariate modeling. J Am Soc Nephrol 2005; 16:S83-S88.
6. Annuk M, Soveri I, Zilmer M, Lind L, Hulthe J, Fellström B: Endothelial function, CRP and oxidative stress in chronic kidney disease. J Nephrol 2005; 18: 721-726.
7. Oberg BP, McMenamin E, Lucas FL, Mc- Monagle E, Morrow J, Ikizler TA, Himmelfarb J: Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004; 65: 1009-1016.
8. Yilmaz MI, Saglam M, Caglar K, Cakir E, Sonmez A, Ozgurtas T, Aydin A, Eyileten T, Ozcan O, Acikel C, Tasar M, Genctoy G, Erbil K, Vural A, Zoccali C: The determinants of endothelial dysfunction in CKD: Oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis 2006; 47: 42-50.
9. Herold K, Moser B, Chen Y, et al: Receptor for advanced glycation end products (RAGE) in a dash to the rescue: Inflammatory signals gone awry in the primal response to stress. J Leukoc Biol 2007; 82: 204-212.
10. Basta G: Receptor for advanced glycation end products and atherosclerosis: From basic mechanisms to clinical implications. Atherosclerosis 2008; 196: 9-21.
11. Geroldi D, Falcone C, Emanuele E: Soluble receptor for advanced glycation end products: From disease marker to potential therapeutic target. Curr Med Chem 2006; 13: 1971-1978.
12. Fanconi C, Emanuele E, D'Angelo A, Buzzi MP, Belvito C, Cuccia M, Geroldi D: Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Atheroscler Thromb Vasc Biol 2005; 25: 1032-1037.
13. Koyama H, Shoji T, Yokoyama H, Motoyama K, Mori K, Fukumoto S, Emoto M, Shoji T, Tamei H, Matsuki H, Sakurai S, Yamamoto Y, Yonekura H, Watanebe T, Yamamoto H, Nishizawa Y: Plasma level of endogenous secretory RAGE is associated with components of metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2005; 25: 2587-2593.
14. Moroz OV, Antson AA, Dodson EJ, Burrell HJ, Grist SJ, Lloyd RM, Maitland NJ, Dodson GG, Wilson KS, Lukanidin E, Bronstein IB: The structure of S100A12 in a hexameric form and its proposed role in receptor signalling. Acta Crystallogr D Biol Crystallogr 2002; 58(part 3):407-413.
15. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, Neurath MF, Slattery T, Beach D, McClary J, Nagashima M, Morser J, Stern D, Schmidt AM: RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeptides. Cell 1999; 97: 889-901.
16. Yang Z, Tao T, Raftery MJ, Youssef P, Di Girolamo N, Geczy CL: Proinflammatory properties of the human S100 protein S100A12. J Leukoc Biol 2001; 69: 986-994.
17. Miranda LP, Tao T, Jones A, Chernushevich I, Standing KG, Geczy CL, Alewood PF: Total chemical synthesis and chemotactic activity of human S100A12 (EN-RAGE). FEBS Lett 2001; 488: 85-90.
18. Foell D, Wittkowski H, Vogl T, Roth J: S100 proteins expressed in phagocytes: A novel group of damage-associated molecular pattern molecules. J Leukoc Biol 2007; 81: 28-37.
19. Foell D, Kucharzik T, Kraft M, Vogl T, Sorg C, Domschke W, Roth J: Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut 2003; 52: 847-853.
20. Foell D, Wittkowski H, Hammerschmidt I, Wulffraat N, Schmeling H, Frosch M, Horneff G, Kuis W, Sorg C, Roth J: Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations. Arthritis Rheum 2003; 50: 1286-1295.
21. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126.
22. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE: Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995; 47: 186-192.
23. Mori Y, Kosaki A, Kishimoto N, Kimura T, Iida K, Fukui M, Nakajima F, Nagahara M, Urakami M, Iwasaka T, Matsubara H: Increased plasma S100A12 (EN-RAGE) levels in hemodialysis patients with atherosclerosis. Am J Nephrol 2009; 29: 18-24.
24. Uchiyama-Tanaka Y, Mori Y, Kosaki A, Kimura T, Moriishi M, Kawanishi H, Matsubara H: Plasma S100A12 concentrations in peritoneal dialysis patients and subclinical chronic inflammatory disease. Ther Apher Dial 2008; 12: 28-32.
25. Basta G, Leonardis D, Mallamaci F, Cutrupi S, Pizzini P, Gaetano L, Tripepi R, Tripepi G, De Caterina R, Zoccali C: Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease. Kidney Int 2010; 77: 225-231.
26. Kalousová M, Hodková M, Kazderová M, Fialová J, Tesar V, Dusilová-Sulková S, Zima T: Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis 2006; 47: 406-411.
27. Kalousová M, Jáschymová M, Mestek O, Hodková M, Kazderová M, Tesar V, Zima T: Receptor for advanced glycation end products - soluble form and gene polymorphisms in chronic haemodialysis patients. Nephrol Dial Transplant 2007; 22: 2020-2026.
28. Franke S, Müller A, Sommer M, Busch M, Kientsch-Engel R, Stein G: Serum levels of homocystein, homocystein metabolites, and of advanced glycation end products (AGEs) in patients after renal transplantation. Clin Nephrol 2003; 59: 88-97.
29. Nakashima A, Carrero JJ, Qureshi AR, Miyamoto T, Anderstam B, Bárány P, Heimbürger O, Stenvinkel P, Lindholm B: Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients. Clin J Am Soc Nephrol 2010; 5: 2213-2219.
30. Basta G, Sironi AM, Lazzerini G, Tel Turco S, Buzzigolu E, Casolaro A, Natali A, Ferrannini E, Gastaldelli A: Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab 2006; 91: 4628-4636.
31. Shishibori T, Oyama Y, Matsushita O, Yamashita K, Furuichi H, Okabe A, Maeta H, Hata Y, Kobayashi R: Three distinct anti-allergic drugs, amlexanox, cromolyn and tranilast, bind to S100A12 and S100A13 of the S100 protein family. Biochem J 1999; 338: 583-589.
32. Basta G, Sironi AM, Lazzerini G, Del Turco S, Buzzigoli E, Casolaro A, Natali A, Ferrannini E, Gastaldelli A: J Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. Clin Endocrinol Metab 2006; 91: 4628-4634.
33. Hasegawa T, Kosaki A, Kimura T, Matsubara H, Mori Y, Okigaki M, Masaki H, Toyoda N, Inoue-Shibata M, Kimura Y, Nishikawa M, Iwasaka T: The regulation of EN-RAGE (S100A12) gene expression in human THP-1 macrophages. Atherosclerosis 2003; 171: 211-218.
34. Foell D, Kane D, Bresnihan B, Vogl T, Nacken W, Sorg C, Fitzgerald O, Roth J: Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. Rheumatology 2003; 42: 1383-1389.
35. Foell D, Seeliger S, Vogl T, Koch HG, Maschek H, Harms E, Sorg C, Roth J: Expression of S100A12 (EN-RAGE) in cystic fibrosis. Thorax 2003; 58: 613-617.
36. Foell D, Ichida F, Vogl T, Yu X, Chen R, Miyawaki T, Sorg C, Roth J: S100A12 (ENRAGE) in monitoring Kawasaki disease. Lancet 2003; 361: 1270-1272.
37. Komatsuda A, Ohtani H, Wakui H, Chyzh KA, Hatakeyama T, Iwamoto K, Maki N, Kimura T, Hitomi J, Sawada K: Increased serum levels of S100A12 in patients with MPO-ANCA-associated glomerulonephritis. Clin Nephrol 2006; 66: 315-321.
38. Kosaki A, Hasegawa T, Kimura T, Iida K, Hitomi J, Matsubara H, Mori Y, Okigaki M, Toyoda N, Masaki H, Inoue-Shibata M, Nishikawa M, Iwasaka T: Increased plasma S100A12 (EN-RAGE) levels in patients with type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 5423-5428.
39. Verma S, Devaraj S, Jialal I: Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation 2006; 113: 2135-2150.
40. Romão JE Jr, Haiashi AR, Elias RM, Luders C, Ferraboli R, Castro MC, Abensur H: Positive acute-phase inflammatory markers in different stages of chronic kidney disease. Am J Nephrol 2006; 26: 59-66.
41. Mahajan N, Bahl A, Dhawan V: C-reactive protein (CRP) up-regulates expression of receptor for advanced glycation end products (RAGE) and its inflammatory ligand ENRAGE in THP-1 cells: Inhibitory effects of atorvastatin. Int J Cardiol 2009; 142: 273-278.
42. Fuellen G, Foell D, Nacken W, Sorg C, Kerkhoff C: Absence of S100A12 in mouse: Implications for RAGE-S100A12 interaction. Trends Immunol 2003; 24: 622-624.
43. Hochepied T, Berger FG, Baumann H, Libert C: Alpha(1)-acid glycoprotein: An acute phase protein with inflammatory and immunomodulating properties. Cytokine Growth Factor Rev 2003; 14: 25-34.
44. Forbes JM, Thorpe SR, Thallas-Bonke V, Pete J, Thomas MC, Deemer ER, Bassal S, El-Osta A, Long DM, Panagiotopoulos S, Jerums G, Osicka TM, Cooper ME: Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol 2005; 16: 2363-2372.